SubRE-LY: new information on dabigatran safety and efficacy in patients with atrial fibrillation
The RE-LY study comparing efficacy and safety of dabigatran versus warfarin in the prevention of thromboembolism in more than 18,000 patients with atrial fibrillation showed that 110 mg dabigatran was safer and equally efficacious and 150 mg dabigatran at least equally safe and more efficacious than warfarin in the prevention of thromboembolism. More recent subanalyses of RE-LY study data provided new insights into dabigatran effects, which may influence the further development of clinical practice. One of the findings was that dabigatran was as efficacious as warfarin in the prevention of thromboembolism after cardioversion of atrial fibrillation irrespective of the level of IN R control and previous use of vitamin K antagonists. New RE-LY subanalyses confirmed the validity of the overall study results showing safety and efficacy of dabigatran in elderly and kidney failure patients with atrial fibrillation.
Key words:
aged; atrial fibrillation; dabigatran etexilate; electric countershock; renal insufficiency, chronic
